DNA/RNA

Description
The FCGR2B gene spans a 15kb genomic region; Gene orientation: centromere -3' FCGR2B 5' -telomere; 8 exons (denoted S1, S2, EC1, EC2, TM, IC1, IC2, IC3). S1 and S2 encode the signal peptide domain, EC1 and EC2 encode the extracellular domain, TM encodes the transmembrane domain and IC1, IC2, IC3 encode the intracytoplasmic region.
Transcription
1.7kb mRNA. Two alternately spliced mRNA exist in humans; FcgRIIb1 and FcgRIIb2 (a 19 aa insertion encoded by IC1 is present in b1 but not in b2). 
Protein
Homology
Contains two immunoglobulin-like C2 domains.
Implicated in
1q21-23 rearrangements in NHL (NnonHodgkins Lymphoma)
Disease NHL (< 5% of cases with 1q21-23 breaks). Prognosis It is now known that cytogenetically determined 1q21-23 breaks can target a diversity of 1q21-23 genes. Early data has suggested a poor prognosis for 1q21 rearrangements in diffuse large cell lymphoma. Cytogenetics Deregulation of the FCGR2B gene by chromosomal translocation was first demonstrated in 3 NHL patients that showed a t(1;22)(q22;q22) in association with a t(14;18)(q32;q21). Two further cases of NHL with rearrangements affecting the FCGR2B region have since been identified. Both cases also showed t(14;18) (see below for description). This suggests a role for this deregulation in lymphoma progression. Hybrid/Mutated gene Dysregulation of the FCGR2B gene has been identified as a consequence of a t(1;22)(q22;q11) (3 patients) and t(1;14)(q21;q32) (1 patient). The FCGR2B coding sequence and promoter region appear to remain intact in these translocations. The principal consequence is overexpression of the Fc gamma RIIb2 isoform of Fc gamma RIIB. Deregulation of FCGR2B most likely occurs as a consequence of Ig gene transcriptional enhancer activity. Other mechanisms may exist; an NHL patient with dup(1)(q21q25) and rearrangement in the FCGR2B region has also been identified.
Abnormal protein
None. Oncogenesis Contribution of FCGR2B deregulation to lymphoma development or progression is currently not known.
